Abstract 9677: Fatty Acid-Binding Protein 4 is a Novel Predictor of Cardiovascular Events in End-Stage Renal Disease
[Background] Fatty acid-binding protein 4 (FABP4/A-FABP/aP2), a lipid chaperone, is expressed in both adipocytes and macrophages and plays important roles in the regulation of insulin sensitivity and the development of atherosclerosis. Recently, FABP4 was found to be secreted from adipocytes. However, little is known about the impact of serum FABP4 concentrations on development of cardiovascular diseases. Here we tested the hypothesis that serum FABP level predicts prognosis of patients with end-stage renal disease (ESRD), a group at high risk for atherosclerosis-associated morbidity and mortality.
[Methods & Results] Biochemical markers including FABP4 were determined in 61 ESRD patients on chronic hemodialysis (HD) and 61 age-, gender- and body mass index (BMI)-matched controls. Serum FABP4 level in females (404.2 ± 30.5 ng/ml) was significantly higher than that in males (315.8 ± 30.0 ng/ml), and the levels in ESRD patients were approximately 20-times higher than those in controls. FABP4 level was decreased by 57.2% after HD and was positively correlated with blood pressure, BMI, and levels of lipids and insulin. Multiple regression analysis indicated that HD duration, BMI, and triglycerides level were independent determinants of serum FABP4 level. Kaplan-Meier survival curves showed that ESRD patients with higher FABP4 levels had higher cardiovascular mortality during the 7-year follow-up period. Cox proportional hazard regression analysis revealed that logarithmically transformed FABP4 level was an independent predictor of cardiovascular death adjusted for age, gender, and HD duration (hazard ratio, 4.89; 95% CI, 1.33-20.23).
[Conclusions] Present findings suggest that FABP4 level, being related to adiposity and metabolic disorders, is a novel predictor of cardiovascular mortality in ESRD.
- © 2011 by American Heart Association, Inc.